150 related articles for article (PubMed ID: 24870789)
1. Is the tumor infiltrating natural killer cell (NK-TILs) count in infiltrating ductal carcinoma of breast prognostically significant?
Rathore AS; Goel MM; Makker A; Kumar S; Srivastava AN
Asian Pac J Cancer Prev; 2014; 15(8):3757-61. PubMed ID: 24870789
[TBL] [Abstract][Full Text] [Related]
2. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Srivastava AN; Makker A; Goel MM
Indian J Cancer; 2013; 50(3):239-44. PubMed ID: 24061465
[TBL] [Abstract][Full Text] [Related]
3. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues.
Bouzidi L; Triki H; Charfi S; Kridis WB; Derbel M; Ayadi L; Sellami-Boudawara T; Cherif B
Clin Breast Cancer; 2021 Dec; 21(6):e738-e747. PubMed ID: 33727019
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
6. Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer.
Rezaeifard S; Talei A; Shariat M; Erfani N
Mol Immunol; 2021 Aug; 136():161-167. PubMed ID: 34171565
[TBL] [Abstract][Full Text] [Related]
7. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
Watanabe T; Hida AI; Inoue N; Imamura M; Fujimoto Y; Akazawa K; Hirota S; Miyoshi Y
Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
[TBL] [Abstract][Full Text] [Related]
8. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
Coronella JA; Spier C; Welch M; Trevor KT; Stopeck AT; Villar H; Hersh EM
J Immunol; 2002 Aug; 169(4):1829-36. PubMed ID: 12165506
[TBL] [Abstract][Full Text] [Related]
9. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
[TBL] [Abstract][Full Text] [Related]
10. Cell Counts, rather than Proportion, of CD8/PD-1 Tumor-Infiltrating Lymphocytes in a Tumor Microenvironment Associated with Pathological Characteristics of Chinese Invasive Ductal Breast Cancer.
Song Q; Shi F; Adair M; Chang H; Guan X; Zhao Y; Li Y; Wu G; Wu J
J Immunol Res; 2019; 2019():8505021. PubMed ID: 31049361
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage.
Pujani M; Jain H; Chauhan V; Agarwal C; Singh K; Singh M
Breast Dis; 2020; 39(2):61-69. PubMed ID: 32310155
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma.
Igari F; Sato E; Horimoto Y; Takahashi Y; Isomura T; Arakawa A; Kitano S; Saito M
Hum Pathol; 2017 Dec; 70():129-138. PubMed ID: 29122657
[TBL] [Abstract][Full Text] [Related]
13. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
Yuen MF; Norris S
Clin Immunol; 2001 Dec; 101(3):264-9. PubMed ID: 11726217
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
15. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
16. Variable natural killer function of tumour-infiltrating lymphocytes from breast carcinomas.
Gudmundsdóttir I; Ogmundsdóttir HM
APMIS; 1992 Aug; 100(8):737-46. PubMed ID: 1325805
[TBL] [Abstract][Full Text] [Related]
17. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic significance of natural killer cell infiltration in hepatocellular carcinoma].
Zhu LY; Zhou J; Liu YZ; Pan WD
Ai Zheng; 2009 Nov; 28(11):1198-202. PubMed ID: 19895742
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
20. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
